Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

1,204 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Impact of the era of diabetes onset in a national care system on the prevalence of retinopathy and microalbuminuria in people living with type 1 diabetes 15 years post-diagnosis: A cross-sectional, real-world observational study.
Lavens A, De Block C, Oriot P, Philips JC, Vandenbroucke M, Crenier L, Nobels F, Mathieu C; Belgian Group of Experts IQED. Lavens A, et al. Among authors: mathieu c. Diabetes Obes Metab. 2025 Aug 28. doi: 10.1111/dom.70049. Online ahead of print. Diabetes Obes Metab. 2025. PMID: 40874300
Relation between disease phenotype and HLA-DQ genotype in diabetic patients diagnosed in early adulthood.
Weets I, Siraux V, Daubresse JC, De Leeuw IH, Féry F, Keymeulen B, Krzentowski G, Letiexhe M, Mathieu C, Nobels F, Rottiers R, Scheen A, Van Gaal L, Schuit FC, Van der Auwera B, Rui M, De Pauw P, Kaufman L, Gorus FK; Belgian Diabetes Registry. Weets I, et al. Among authors: mathieu c. J Clin Endocrinol Metab. 2002 Jun;87(6):2597-605. doi: 10.1210/jcem.87.6.8613. J Clin Endocrinol Metab. 2002. PMID: 12050221 Free article.
Insulin needs after CD3-antibody therapy in new-onset type 1 diabetes.
Keymeulen B, Vandemeulebroucke E, Ziegler AG, Mathieu C, Kaufman L, Hale G, Gorus F, Goldman M, Walter M, Candon S, Schandene L, Crenier L, De Block C, Seigneurin JM, De Pauw P, Pierard D, Weets I, Rebello P, Bird P, Berrie E, Frewin M, Waldmann H, Bach JF, Pipeleers D, Chatenoud L. Keymeulen B, et al. Among authors: mathieu c. N Engl J Med. 2005 Jun 23;352(25):2598-608. doi: 10.1056/NEJMoa043980. N Engl J Med. 2005. PMID: 15972866 Free article. Clinical Trial.
Hyperglycaemic clamp test for diabetes risk assessment in IA-2-antibody-positive relatives of type 1 diabetic patients.
Vandemeulebroucke E, Keymeulen B, Decochez K, Weets I, De Block C, Féry F, Van de Velde U, Vermeulen I, De Pauw P, Mathieu C, Pipeleers DG, Gorus FK; Belgian Diabetes Registry. Vandemeulebroucke E, et al. Among authors: mathieu c. Diabetologia. 2010 Jan;53(1):36-44. doi: 10.1007/s00125-009-1569-3. Epub 2009 Nov 7. Diabetologia. 2010. PMID: 19898832 Free article.
Efficacy and safety of insulin degludec in a flexible dosing regimen vs insulin glargine in patients with type 1 diabetes (BEGIN: Flex T1): a 26-week randomized, treat-to-target trial with a 26-week extension.
Mathieu C, Hollander P, Miranda-Palma B, Cooper J, Franek E, Russell-Jones D, Larsen J, Tamer SC, Bain SC; NN1250-3770 (BEGIN: Flex T1) Trial Investigators. Mathieu C, et al. J Clin Endocrinol Metab. 2013 Mar;98(3):1154-62. doi: 10.1210/jc.2012-3249. Epub 2013 Feb 7. J Clin Endocrinol Metab. 2013. PMID: 23393185 Free PMC article. Clinical Trial.
1,204 results